The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

Nithin D. Adappa; Chi Kwang Sung; Bryan Choi; Tian Gui Huang; Eric M. Genden; Edward J. Shin

doi:10.1016/j.otohns.2008.05.001

The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

Nithin D. Adappa
, Chi Kwang Sung
, Bryan Choi
, Tian Gui Huang
, Eric M. Genden
, Edward J. Shin

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Objective: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model. Study Design: In vitro and in vivo testing of immune therapy for SCC. Methods: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival. Results: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001). Conclusion: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.

Original language	English
Pages (from-to)	442-448
Number of pages	7
Journal	Otolaryngology - Head and Neck Surgery
Volume	139
Issue number	3
DOIs	https://doi.org/10.1016/j.otohns.2008.05.001
State	Published - Sep 2008

Access to Document

10.1016/j.otohns.2008.05.001

Cite this

@article{02990a0132544cc1b2070ed25b3fcb4c,

title = "The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer",

abstract = "Objective: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model. Study Design: In vitro and in vivo testing of immune therapy for SCC. Methods: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival. Results: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001). Conclusion: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.",

author = "Adappa, \{Nithin D.\} and Sung, \{Chi Kwang\} and Bryan Choi and Huang, \{Tian Gui\} and Genden, \{Eric M.\} and Shin, \{Edward J.\}",

year = "2008",

month = sep,

doi = "10.1016/j.otohns.2008.05.001",

language = "English",

volume = "139",

pages = "442--448",

journal = "Otolaryngology - Head and Neck Surgery",

issn = "0194-5998",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

AU - Adappa, Nithin D.

AU - Sung, Chi Kwang

AU - Choi, Bryan

AU - Huang, Tian Gui

AU - Genden, Eric M.

AU - Shin, Edward J.

PY - 2008/9

Y1 - 2008/9

N2 - Objective: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model. Study Design: In vitro and in vivo testing of immune therapy for SCC. Methods: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival. Results: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001). Conclusion: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.

AB - Objective: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model. Study Design: In vitro and in vivo testing of immune therapy for SCC. Methods: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival. Results: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001). Conclusion: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.

UR - https://www.scopus.com/pages/publications/49549104476

U2 - 10.1016/j.otohns.2008.05.001

DO - 10.1016/j.otohns.2008.05.001

M3 - Article

C2 - 18722228

AN - SCOPUS:49549104476

SN - 0194-5998

VL - 139

SP - 442

EP - 448

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

IS - 3

ER -

The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

Abstract

Access to Document

Fingerprint

Cite this